• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Neogen Corporation

    8/20/24 1:34:59 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    S-8 1 neog-20240819.htm S-8 S-8

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    NEOGEN CORPORATION

    (Exact name of Registrant as specified in its charter)

     

     

     

    Michigan

    38-2364843

    (State or Other Jurisdiction of

    Incorporation or Organization)

    (I.R.S. Employer

    Identification Number.)

     

     

     

    620 Lesher Place, Lansing, Michigan

    48912

    (Address of principal executive offices)

    (Zip code)

    Neogen Corporation 2021 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Amy M. Rocklin

    Chief Legal & Compliance Officer, Corporate Secretary

    Neogen Corporation

    620 Lesher Place

    Lansing, Michigan 48912

    (Name and address of agent for service)

    (517) 372-9200

    (Telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     


     

     

    PART I

    INFORMATION REQUIRED IN PROSPECTUS

    The documents containing the information required in this Part I will be delivered to the participants in the Plan, as specified in Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be filed with the Securities and Exchange Commission (the “Commission”) as part of this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.

    Incorporation of Documents By Reference.

    The following documents filed with the Commission by Neogen Corporation (the “Registrant”) pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference in this Registration Statement:

    (a) The Registrant’s latest Annual Report on Form 10-K filed with the Commission;

    (b) All other reports or documents filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report on Form 10-K referenced in (a) above; and

    (c) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement filed pursuant to Section 12 of the Exchange Act.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information in any filing made by the Registrant with the Commission that is expressly furnished rather than filed, including all information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such filing.

    Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein by reference modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4.

    Description of Securities.

    Not applicable.

    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

     

     

    Item 6.

    Indemnification of Directors and Officers.

    The Registrant’s articles of incorporation provide that a director of the Registrant will not be liable to the Registrant or its shareholders for monetary damages for any breach of the director’s fiduciary duty in connection with any action or omission on the part of the director, except for liability for (i) financial benefits to which the director was not entitled, (ii) intentional infliction of harm on the Registrant or its shareholders, (iii) improper distributions or loans in violation of Section 551 of the Michigan Business Corporation Act (the “MBCA”), or (iv) intentional criminal acts. These provisions, however, do not affect liability under the Securities Act.


    The Registrant’s bylaws include provisions that require the Registrant to indemnify its directors, officers, and employees with respect to any liability arising out of such positions to the fullest extent allowable under the MBCA. The provisions of the MBCA are broad enough to permit indemnification with respect to liabilities arising under the Securities Act and Michigan Uniform Securities Act.

    The limitation of liability and indemnification provisions in the Registrant’s articles of incorporation and bylaws may discourage shareholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against the Registrant’s directors and officers, even though such an action, if successful, might otherwise benefit the Registrant and its shareholders. However, these provisions do not limit or eliminate the Registrant’s rights, or those of any shareholder, to seek non-monetary relief such as injunction or rescission in the event of a breach of a director’s duty of care. Moreover, the provisions will not alter the liability of directors under the federal securities laws. An investment in the Registrant may, however, be adversely affected to the extent that, in a class action or direct suit, the Registrant pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

    The Registrant has purchased a policy of directors’ and officers’ insurance that insures both the Registrant and its officers and directors against expenses and liabilities of the type normally insured against under such policies, including the expenses of the indemnification described above and liabilities under the Securities Act.

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.

     


     

    Item 8.

    Exhibits.

     

     

     

    Exhibit No.

    Description

     

     

    4.1

    Restated Articles of Incorporation filed February 14, 2000, as amended on November 23, 2011 (incorporated by reference to Exhibit 3.1 to the Quarterly Report filed December 30, 2011).

     

     

    4.2

    Certificate of Amendment to Articles of Incorporation filed on October 11, 2010 (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed July 30, 2020).

     

     

    4.3

    Certificate of Amendment to Articles of Incorporation filed on November 20, 2018 (incorporated by reference to Exhibit 3 to the Quarterly Report on Form 10-Q filed December 28, 2018).

     

     

    4.4

    Certificate of Amendment to Articles of Incorporation filed on March 14, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed March 17, 2022).

     

     

     

    4.5

     

    Certificate of Amendment to Articles of Incorporation filed on September 1, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed September 1, 2022).

     

     

     

    4.6

     

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed October 31, 2023).

     

     

     

    5.1

     

    Opinion of Varnum LLP.

     

     

    23.1

    Consent of Independent Registered Public Accounting Firm BDO USA, LLP.

     

     

    23.2

     

    Consent of Varnum LLP (included in the opinion filed as Exhibit 5.1 to this registration statement.)

     

     

    24.1

    Power of Attorney (included on the signature page of this registration statement).

     

     

     

    99

     

    Neogen Corporation 2021 Employee Stock Purchase Plan (incorporated by reference to Appendix A to the Proxy Statement on Schedule 14A filed August 31, 2021).

     

     

     

    107

     

    Filing Fee Table.

    Item 9.

    Undertakings.

    (a)

    The Registrant hereby undertakes:

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering


     

     

    price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement;

    (iii)

    to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the registration statement; and

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offer thereof.

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

     

    (b)

    The Registrant hereby undertakes that, for the purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lansing, State of Michigan, on August 20, 2024.

     

     

     

     

     

     

     

     

     

    NEOGEN CORPORATION

     

     

     

     

     

     

    By:

    /s/ JOHN E. ADENT

     

     

     

    John E. Adent

     

     

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned officers and directors of NEOGEN CORPORATION, a Michigan corporation (the “Company”), hereby constitutes and appoints JOHN E. ADENT and DAVID H. NAEMURA, and each of them, the true and lawful attorneys-in-fact and agents of the undersigned, each with the power of substitution for him in any and all capacities, with full power and authority in said attorneys-in-fact and agents and in any one or more of them, to sign, execute and affix his seal thereto and file the proposed registration statement on Form S-8 to be filed by the Company under the Securities Act of 1933, as amended, which registration statement relates to the registration and issuance of the Company’s Common Shares, par value $0.16 a share, pursuant to the Neogen Corporation 2021 Employee Stock Purchase Plan, and any of the documents relating to such registration statement; any and all amendments to such registration statement, including any amendment thereto changing the amount of securities for which registration is being sought, and any post-effective amendment, with all exhibits and any and all documents required to be filed with respect thereto with any regulatory authority; granting unto said attorneys, each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises in order to effectuate the same as fully to all intents and purposes as he might or could do if personally present, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, may lawfully do or cause to be done by virtue hereof.

    [REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK]

     

     


    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

    President & Chief Executive Officer

    /s/ John E. Adent

    (Principal Executive Officer)

    August 20, 2024

    John E. Adent

    /s/ David H. Naemura

    Chief Financial Officer

    August 20, 2024

    David H. Naemura

    (Principal Financial Officer)

     

     

     

     

    /s/ John P. Moylan

    Chief Accounting Officer

    August 20, 2024

    John P. Moylan

    (Principal Accounting Officer)

     

     

     

     

     

     

     

    /s/ James C. Borel

    Chairman of the Board of Directors

    August 20, 2024

    James C. Borel

     

     

    /s/ William T. Boehm, Ph.D.

    Director

    August 20, 2024

    William T. Boehm, Ph.D.

     

     

     

     

    /s/ Jeffrey D. Capello

    Director

    August 20, 2024

    Jeffrey D. Capello

     

     

     

    /s/ Ronald D. Green, Ph.D.

    Director

    August 20, 2024

    Ronald D. Green, Ph.D.

     

     

     

     

    /s/ Aashima Gupta

    Director

    August 20, 2024

    Aashima Gupta

     

     

     

    /s/ Raphael A. Rodriguez

    Director

    August 20, 2024

    Raphael A. Rodriguez

     

     

    /s/ James P. Tobin

    Director

    August 20, 2024

    James P. Tobin

     

     

    /s/ Catherine E. Woteki, Ph.D.

    Director

    August 20, 2024

    Catherine E. Woteki, Ph.D.

     


    Get the next $NEOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution

    Neogen Corporation (NASDAQ:NEOG) is voluntarily recalling all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of 10 mL/50 mg product vials. Neogen received a number of reports of adverse events in horses following intraarticular injections of this product, which is inconsistent with its labeled, intended use. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use. While the company's

    1/28/26 6:27:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces Two Senior Leadership Appointments

    Neogen Corporation (NASDAQ:NEOG) today announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer, effective January 5, 2026, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety, effective January 7, 2026. As Senior Vice President and General Manager for Neogen's Food Safety business unit, Dr. Ranalli will have full P&L responsibility for Neogen's global Food Safety portfolio and will develop and execute the global strategy for continued innovation and growth, including marketing, research and development, and government and regulatory affairs. She joins Neogen from QuidelOrtho, where she served as Senior Vice Presiden

    1/5/26 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,279 worth of shares (137 units at $9.33) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/16/26 9:04:01 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Senior Vice President Ranalli Tamara A. was granted 101,626 shares (SEC Form 4)

    4/A - NEOGEN CORP (0000711377) (Issuer)

    1/29/26 10:30:09 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Senior Vice President Ranalli Tamara A. was granted 50,813 shares (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/26/26 9:34:27 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    SEC Filings

    View All

    SEC Form 10-Q filed by Neogen Corporation

    10-Q - NEOGEN CORP (0000711377) (Filer)

    1/8/26 4:07:39 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    1/8/26 7:03:05 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    10/30/25 8:47:15 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on January 8, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 82072 The live webcast can be accessed through Neogen's Investor Relations webpage, investors.neogen.com, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusion of the call and c

    12/18/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces First-Quarter 2026 Results

    Revenue of $209.2 million Net Income of $36.3 million; Adjusted Net Income1 of $9.4 million Adjusted EBITDA1 of $35.5 million Completed divestiture of Cleaners & Disinfectants business, repaid $100.0 million of debt Welcomed Mike Nassif as Chief Executive Officer and President, effective August 11 Restructuring actions taken at the end of September to right-size the cost base Reaffirming full-year outlook 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2025. "I see tremendous opportunity ahead to leverage Neogen's strong, longstanding l

    10/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care